Fugitive Discovered Working Under Alias in Biotech Industry Amid Legal Battles Involving AstraZeneca and Lilly
A Rhode Island fugitive who had been on the most-wanted list was recently uncovered as having worked under a false identity in the biotech sector.
The revelation raised questions about how the individual avoided detection for roughly twenty years and what vetting processes allowed him to be hired by at least one biotech firm.
In related news, a U.S. court rejected AstraZeneca’s attempt to block a Maine law that governs how drugmakers can contract with pharmacies, a decision that could affect industry pricing arrangements.
Additionally, a hospital has filed a lawsuit against Eli Lilly, adding another legal dispute to the pharmaceutical landscape this week.
The column highlights the convergence of personal misconduct and broader regulatory challenges facing the sector.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that